Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 9, 2003, Pages 1197-1204

  Sievert, W ^a,i   Batey, R ^b   Mollison, L ^c   Pianko, S ^a   Mcdonald, J ^d   Marinos, G ^e   Reed, W ^c   Warner, S ^a   Bowden, S ^f   De Solom, R ^g   Bhathal, P ^h  

^a MONASH UNIVERSITY   (Australia)

^b JOHN HUNTER HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d WOLLONGONG HOSPITAL   (Australia)

^e PRINCE OF WALES HOSPITAL   (Australia)

^f VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^g Schering Plough Pty Ltd   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; INTERFERON; PLACEBO; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; CHOLECYSTITIS; CHRONIC HEPATITIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEMOGLOBIN DETERMINATION; HEPATITIS C; HUMAN; HYPOTHYROIDISM; IMMUNOTHERAPY; INFECTION RATE; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; SIDE EFFECT; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TONSILLITIS; URTICARIA; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME;

EID: 0038189662     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01544.x     Document Type: Article

References (23)

1. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998: 339: 1485-92.
2. Poynard T. Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998: 352: 1426-32.
3. Manns MP, McHutchison JG. Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
4. Fried MW, Shiffman ML. Reddy RK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002: 347: 975-82.
5. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998: 339: 1493-9.
6. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998: 282: 103-7.
7. Herrmann E. Neumann AU, Schmidt JM, Zeuzem S. Hepatitis C virus kinetics. Antiviral Ther 2000; 5: 85-90.
8. Cheng SJ. Bonis PAL, Lau J. Pham NQ, Wong JB. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 2001; 33: 231-40.
9. Cummings KJ. Lee SM. West ES, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon. A meta-analysis of randomized trials. J Am Med Assoc 2001: 285: 193-9.
10. San Miguel R. Guillen F. Cabases JM, Buti M. Meta-analysis: combination therapy with interferon-α 2a/b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon. Aliment Pharmacol Ther 2002: 16: 1611-21.
11. Kjaergard LL, Krogsgaard K. Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. Br Med J 2001; 323: 1151-5.
12. Ishak K. Baptista A. Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
13. Ebeling F, Lappalainen M, Vuoristo M, et al. Factors predicting interferon treatment response in patients with chronic hepatitis: late viral clearance does not preclude a sustained response. Am J Gastroenterol 2001; 96: 1237-42.
14. Pockros PJ. Tong M. Lee WM, et al. Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. J Viral Hepat 1998: 5: 271-6.
15. Rosen HR, Ribeiro RR. Weinberger L, et al. Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. J Hepatol 2002: 37: 124-30.
16. Ferenci P, Brunner H. Nachbaur K, et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001: 34: 1006-11.
17. Bekkering FC. Brouwer JT, Leroux-Roels G, Van Vlierberghe H, Elewaut A. Schalm S. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol 1998: 28: 960-4.
18. Malik AH, Kumar KS, Malet PF, et al. A randomized trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon. Aliment Pharmacol Ther 2002: 16: 381-8.
19. McHutchison JG, Poynard T, Esteban-Mur R, et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002: 35: 688-93.
20. Nelson DR, Marousis CG. Davis GL. et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997: 158: 1473-81.
21. Buti M, Sanchez-Avila F. Lurie Y, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002: 35: 930-6.
22. Jacobson I, Russo M, Brown R, et al. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: a trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers. Hepatology 2001; 34(4 Part 2): 338A.
23. Shiffman M and the HALT-C Trial Investigators. Retreatment of HCV non-responders with peginterferon and ribavirin: results from the lead-in phase of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial [Abstract]. Hepatology 2002: 36(4 Part 2): 295A.